Ut Bene Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 1 Day
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -15.61%
- Profit Growth 0.78%
- Net Worth 3.92%
- Total Assets 23.88%
About Ut Bene Pharma
Ut Bene Pharma Private Limited (UBPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 February 2011 and has a history of 14 years. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jagdish Harsh and Deepti Sahni serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74900DL2011PTC213482
-
Company No.
213482
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Feb 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Ut Bene Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagdish Harsh
|
Director | 07-Feb-2011 | Current |
|
Deepti Sahni
|
Director | 07-Feb-2011 | Current |
Financial Performance of Ut Bene Pharma.
Ut Bene Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 15.61% decrease. The company also saw a slight improvement in profitability, with a 0.78% increase in profit. The company's net worth moved up by a moderate rise of 3.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ut Bene Pharma?
In 2018, Ut Bene Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Mobiloitte FoundationJagdish Harsh and Deepti Sahni are mutual person
-
Mobiloitte Technologies India Private LimitedJagdish Harsh and Deepti Sahni are mutual person
-
Trikon Networks Private LimitedJagdish Harsh is a mutual person
-
Enlaces & Listas Health Private Limited
Jagdish Harsh and Deepti Sahni are mutual person
-
Matrix Secure Applications (Opc) Private Limited
Deepti Sahni is a mutual person
-
Bluetick Ventures Private Limited
Deepti Sahni is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ut Bene Pharma?
Unlock and access historical data on people associated with Ut Bene Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ut Bene Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ut Bene Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.